Sonja Kleinlogel

Dr. Sonja Kleinlogel

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2015 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MWMichiel van Wyk
Michiel van Wyk
JPJustyna Pielecka-Fortuna
Justyna Pielecka-Fortuna
SLSiegrid Löwel
Siegrid Löwel
SKSonja Kleinlogel
Sonja Kleinlogel
Photoreceptor degeneration is one of the most prevalent causes of blindness. Despite photoreceptor loss, the inner retina and central visual pathways remain intact over an extended time period, which has led to creative optogenetic approaches to restore light sensitivity in the surviving inner retina. The major drawbacks of all optogenetic tools recently developed and tested in mouse models are their low light sensitivity and lack of physiological compatibility. Here we introduce a next-generation optogenetic tool, Opto-mGluR6, designed for retinal ON-bipolar cells, which overcomes these limitations. We show that Opto-mGluR6, a chimeric protein consisting of the intracellular domains of the ON-bipolar cell–specific metabotropic glutamate receptor mGluR6 and the light-sensing domains of melanopsin, reliably recovers vision at the retinal, cortical, and behavioral levels under moderate daylight illumination. Many blind patients have lost the light-sensing photoreceptor cells in their retinas, while deeper retinal cell layers, which normally cannot sense light, remain relatively intact. Promising new “optogenetic” therapies under preclinical evaluation use a modified virus to introduce light-sensitive proteins into surviving retinal cells, turning them into “replacement photoreceptors” and thereby restoring vision. However, several factors limit the feasibility of a clinical optogenetic therapy. For example, current light-sensing proteins only respond to unnaturally high light intensities and employ foreign signaling mechanisms to activate the target retinal cells. To overcome these limitations, we have engineered a cell-tailored light-sensing protein called Opto-mGluR6, which responds to daylight and activates a native signaling pathway within the target cells. Opto-mGluR6 is a chimeric protein composed of the light-sensing domains of the retinal photopigment melanopsin and the ON-bipolar cell–specific metabotropic glutamate receptor mGluR6, which amplifies the signal and ensures retinal responsiveness to daylight. We show that Opto-mGluR6 reliably recovers vision in the mouse, moving towards a clinical optogenetic therapy for patients suffering from photoreceptor degeneration.

20 October 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
Jakub KralikJakub Kralik
Jakub Kralik
MWMichiel van Wyk
Michiel van Wyk
NSNino Stocker
Nino Stocker
SKSonja Kleinlogel
Sonja Kleinlogel
Optogenetic gene therapies to restore vision are in clinical trials. Whilst current clinical approaches target the ganglion cells, the output neurons of the retina, new molecular tools enable efficient targeting of the first order retinal interneurons, the bipolar cells, with the potential to restore a higher quality of vision. Here we investigate retinal signaling and behavioral vision in blind mice treated with bipolar cell targeted optogenetic gene therapies. All tested tools, including medium-wave opsin, Opto-mGluR6, and two new melanopsin based chimeras restored visual acuity and contrast sensitivity. The best performing opsin was a melanopsin-mGluR6 chimera, which in some cases restored visual acuities and contrast sensitivities that match wild-type animals. Light responses from the ganglion cells were robust with diverse receptive-field types, inferring elaborate inner retinal signaling. Our results highlight the potential of bipolar cell targeted optogenetics to recover high-level vision in human patients with end-stage retinal degenerations.

29 March 2017 in Frontiers in Neuroscience
Verified
Journal Article
Open access
MWMichiel van Wyk
Michiel van Wyk
EHElmar C. Hulliger
Elmar C. Hulliger
LGLara Girod
Lara Girod
AEAndreas Ebneter
Andreas Ebneter
SKSonja Kleinlogel
Sonja Kleinlogel
Recent studies have demonstrated the safety and efficacy of ocular gene therapy based on adeno-associated viral vectors (AAVs). Accordingly, a surge in promising new gene therapies is entering clinical trials, including the first optogenetic therapy for vision restoration. To date, optogenetic therapies for vision restoration target either the retinal ganglion cells (GCs) or presynaptic ON-bipolar cells (OBCs). Initiating light responses at the level of the OBCs has significant advantages over optogenetic activation of GCs. For example, important neural circuitries in the inner retina, which shape the receptive fields of GCs, remain intact when activating the OBCs. Current drawbacks of AAV-mediated gene therapies targeting OBCs include (1) a low transduction efficiency, (2) off-target expression in unwanted cell populations and (3) a poor performance in human tissue compared to the murine retina. Here, we examined side-by-side the performance of three state-of-the art AAV capsid variants, AAV7m8, AAVBP2 and AAV7m8(Y444F) in combination with the 4×GRM6-SV40 promoter construct in the healthy and degenerated mouse retina and in human post-mortem retinal explants. We find that (1) the 4×GRM6-SV40 promoter is not OBC specific, (2) that all AAV variants possess broad cellular transduction patterns, with differences between the transduction patterns of capsid variants AAVBP2 and AAV7m8 and, most importantly, (3) that all vectors target OBCs in healthy tissue but not in the degenerated rd1 mouse model, potentially limiting the possibilities for an OBC-targeted optogenetic therapy for vision restoration in the blind.

1 January 2016 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Closed access
SKSonja Kleinlogel
Sonja Kleinlogel
Optogenetics has taken biomedical research by storm. The power and precision at which light-gated ion channels control cellular excitability in diverse biological systems has convinced researchers of an optical future. Growing interest in optical methods has sparked the development of multiple new optogenetic tools, which allow precise control of numerous cellular processes. Among these new tools are the light-activatable G-protein coupled receptors (GPCRs) or Opto-GPCRs. The extent of the GPCR family, which in humans alone encompasses approximately 800 different proteins, and the immense therapeutic potential of Opto-GPCRs predict a big future for this juvenile field. Here the different approaches taken to design Opto-GPCRs are reviewed, outlining the advantages and disadvantages of each method for physiological and potential clinical application.

3 November 2016 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MPMichael Perny
Michael Perny
LMLukas Muri
Lukas Muri
HDHeather Dawson
Heather Dawson
SKSonja Kleinlogel
Sonja Kleinlogel
Channelrhodopsin-2 (ChR2) has become a celebrated research tool and is considered a promising potential therapeutic for neurological disorders. While making its way into the clinic, concerns about the safety of chronic ChR2 activation have emerged; in particular as the high-intensity blue light illumination needed for ChR2 activation may be phototoxic. Here we set out to quantify for the first time the cytotoxic effects of chronic ChR2 activation. We studied the safety of prolonged illumination on ChR2(D156A)-expressing human melanoma cells as cancer cells are notorious for their resistance to killing. Three days of illumination eradicated the entire ChR2(D156A)-expressing cell population through mitochondria-mediated apoptosis, whereas blue light activation of non-expressing control cells did not significantly compromise cell viability. In other words, chronic high-intensity blue light illumination alone is not phototoxic, but prolonged ChR2 activation induces mitochondria-mediated apoptosis. The results are alarming for gain-of-function translational neurological studies but open the possibility to optogenetically manipulate the viability of non-excitable cells, such as cancer cells. In a second set of experiments we therefore evaluated the feasibility to put melanoma cell proliferation and apoptosis under the control of light by transdermally illuminating in vivo melanoma xenografts expressing ChR2(D156A). We show clear proof of principle that light treatment inhibits and even reverses tumor growth, rendering ChR2s potential tools for targeted light-therapy of cancers.

18 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJonas Streit
Jonas Streit
SKSonja Kleinlogel
Sonja Kleinlogel
Voltage-gated ion channels (VGCs) are prime targets for the pharmaceutical industry, but drug profiling on VGCs is challenging, since drug interactions are confined to specific conformational channel states mediated by changes in transmembrane potential. Here we combined various optogenetic tools to develop dynamic, high-throughput drug profiling assays with defined light-step protocols to interrogate VGC states on a millisecond timescale. We show that such light-induced electrophysiology (LiEp) yields high-quality pharmacological data with exceptional screening windows for drugs acting on the major cardiac VGCs, including hNav1.5, hKv1.5 and hERG. LiEp-based screening remained robust when using a variety of optogenetic actuators (ChR2, ChR2(H134R), CatCh, ChR2-EYFP-βArchT) and different types of organic (RH421, Di-4-ANBDQPQ, BeRST1) or genetic voltage sensors (QuasAr1). The tractability of LiEp allows a versatile and precise alternative to state-of-the-art VGC drug screening platforms such as automated electrophysiology or FLIPR readers.